JP2020528938A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528938A5 JP2020528938A5 JP2020527861A JP2020527861A JP2020528938A5 JP 2020528938 A5 JP2020528938 A5 JP 2020528938A5 JP 2020527861 A JP2020527861 A JP 2020527861A JP 2020527861 A JP2020527861 A JP 2020527861A JP 2020528938 A5 JP2020528938 A5 JP 2020528938A5
- Authority
- JP
- Japan
- Prior art keywords
- galactosemia
- pharmaceutical composition
- aldose reductase
- alkyl
- reductase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000027472 Galactosemias Diseases 0.000 claims description 51
- 239000003288 aldose reductase inhibitor Substances 0.000 claims description 32
- 229940118148 Aldose reductase inhibitor Drugs 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 20
- 208000010877 cognitive disease Diseases 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 11
- 230000009251 neurologic dysfunction Effects 0.000 claims description 10
- 208000015015 neurological dysfunction Diseases 0.000 claims description 10
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 claims description 9
- 208000002177 Cataract Diseases 0.000 claims description 7
- 208000017442 Retinal disease Diseases 0.000 claims description 6
- 230000004064 dysfunction Effects 0.000 claims description 6
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 claims description 5
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 206010010904 Convulsion Diseases 0.000 claims description 3
- 208000001344 Macular Edema Diseases 0.000 claims description 3
- 206010025415 Macular oedema Diseases 0.000 claims description 3
- 208000036626 Mental retardation Diseases 0.000 claims description 3
- 206010038923 Retinopathy Diseases 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 230000036461 convulsion Effects 0.000 claims description 3
- 201000010230 macular retinal edema Diseases 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 210000005036 nerve Anatomy 0.000 claims description 3
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 3
- 208000015124 ovarian disease Diseases 0.000 claims description 3
- 201000004535 ovarian dysfunction Diseases 0.000 claims description 3
- 231100000543 ovarian dysfunction Toxicity 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 210000001742 aqueous humor Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 claims description 2
- 229950010170 epalrestat Drugs 0.000 claims description 2
- CHNUOJQWGUIOLD-UHFFFAOYSA-N epalrestate Natural products C=1C=CC=CC=1C=C(C)C=C1SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-UHFFFAOYSA-N 0.000 claims description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 2
- 229960000367 inositol Drugs 0.000 claims description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 229910052799 carbon Inorganic materials 0.000 claims 12
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 229940002612 prodrug Drugs 0.000 claims 6
- 239000000651 prodrug Substances 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 claims 4
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 125000004995 haloalkylthio group Chemical group 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 3
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000000463 material Substances 0.000 description 3
- 229940126062 Compound A Drugs 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022169791A JP7541064B2 (ja) | 2017-07-28 | 2022-10-24 | ガラクトース血症を処置するための組成物および方法 |
| JP2024135647A JP2024159794A (ja) | 2017-07-28 | 2024-08-15 | ガラクトース血症を処置するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762538443P | 2017-07-28 | 2017-07-28 | |
| US62/538,443 | 2017-07-28 | ||
| PCT/US2018/044199 WO2019023648A1 (en) | 2017-07-28 | 2018-07-27 | COMPOSITIONS AND METHODS FOR TREATING GALACTOSEMIA |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022169791A Division JP7541064B2 (ja) | 2017-07-28 | 2022-10-24 | ガラクトース血症を処置するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020528938A JP2020528938A (ja) | 2020-10-01 |
| JP2020528938A5 true JP2020528938A5 (https=) | 2021-09-09 |
| JP7307059B2 JP7307059B2 (ja) | 2023-07-11 |
Family
ID=65039851
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020527861A Active JP7307059B2 (ja) | 2017-07-28 | 2018-07-27 | ガラクトース血症を処置するための組成物および方法 |
| JP2022169791A Active JP7541064B2 (ja) | 2017-07-28 | 2022-10-24 | ガラクトース血症を処置するための組成物および方法 |
| JP2024135647A Pending JP2024159794A (ja) | 2017-07-28 | 2024-08-15 | ガラクトース血症を処置するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022169791A Active JP7541064B2 (ja) | 2017-07-28 | 2022-10-24 | ガラクトース血症を処置するための組成物および方法 |
| JP2024135647A Pending JP2024159794A (ja) | 2017-07-28 | 2024-08-15 | ガラクトース血症を処置するための組成物および方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11590131B2 (https=) |
| EP (2) | EP4417260A3 (https=) |
| JP (3) | JP7307059B2 (https=) |
| CN (3) | CN119633117A (https=) |
| AU (2) | AU2018307964B2 (https=) |
| CA (1) | CA3071114A1 (https=) |
| DK (1) | DK3658142T3 (https=) |
| ES (1) | ES2983586T3 (https=) |
| FI (1) | FI3658142T3 (https=) |
| HR (1) | HRP20240840T1 (https=) |
| HU (1) | HUE067079T2 (https=) |
| IL (2) | IL272246B2 (https=) |
| LT (1) | LT3658142T (https=) |
| MX (2) | MX2020001057A (https=) |
| PL (1) | PL3658142T3 (https=) |
| PT (1) | PT3658142T (https=) |
| SG (1) | SG11202000730QA (https=) |
| SI (1) | SI3658142T1 (https=) |
| WO (1) | WO2019023648A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL272246B2 (en) * | 2017-07-28 | 2026-01-01 | Applied Therapeutics Inc | History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications |
| JP7457033B2 (ja) * | 2019-02-28 | 2024-03-27 | 石薬集団中奇制薬技術（石家庄）有限公司 | アルドース還元酵素阻害剤の塩、及びその製造方法と使用 |
| CN113840825A (zh) * | 2019-04-01 | 2021-12-24 | 应用治疗公司 | 醛糖还原酶抑制剂 |
| WO2020227430A1 (en) | 2019-05-07 | 2020-11-12 | University Of Miami | Treatment and detection of inherited neuropathies and associated disorders |
| CA3153108A1 (en) * | 2019-10-08 | 2021-04-15 | Riccardo Perfetti | Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency |
| IL297779A (en) * | 2020-05-01 | 2022-12-01 | Applied Therapeutics Inc | Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency |
| WO2025104239A1 (en) | 2023-11-16 | 2025-05-22 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of classic galactosemia |
| WO2025219948A1 (en) * | 2024-04-17 | 2025-10-23 | Assia Chemical Industries Ltd. | Crystalline forms of govorestat |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0189272A3 (en) | 1985-01-17 | 1987-08-19 | Fujisawa Pharmaceutical Co., Ltd. | New furanone derivatives, processes for preparation thereof and use thereof |
| ES2032749T3 (es) | 1985-11-07 | 1993-03-01 | Pfizer Inc. | Acidos oxoftalazinil-aceticos heterociclicos. |
| CA1299178C (en) | 1985-11-07 | 1992-04-21 | Banavara Lakshmana Mylari | Heterocyclic oxophtalazinyl acetic acids |
| US4939140A (en) * | 1985-11-07 | 1990-07-03 | Pfizer Inc. | Heterocyclic oxophthalazinyl acetic acids |
| AU7386887A (en) | 1986-06-12 | 1987-12-17 | American Home Products Corporation | Method of stimulating the immune system with tolrestat;(n-((5 -(trifluoromethyl)-6-methoxy-1-naphthenyl)thioxomethyl)-n-me hylglycine) |
| US4868301A (en) | 1987-06-09 | 1989-09-19 | Pfizer Inc. | Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains |
| CA1307537C (en) * | 1987-12-23 | 1992-09-15 | Jay E. Wrobel | N-naphthoylglycines as aldose reductase inhibitors |
| WO1989006651A1 (en) | 1988-01-19 | 1989-07-27 | Pfizer Inc. | 1h-indazole-3-acetic acids as aldose reductase inhibitors |
| US4996204A (en) | 1989-05-11 | 1991-02-26 | Pfizer Inc. | Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors |
| US4954629A (en) | 1989-05-11 | 1990-09-04 | Pfizer Inc. | Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof |
| FR2647676A1 (fr) | 1989-06-05 | 1990-12-07 | Union Pharma Scient Appl | Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase |
| WO1991009019A1 (en) | 1989-12-15 | 1991-06-27 | Pfizer Inc. | Substituted oxophthalazinyl acetic acids and analogs thereof |
| JPH0495025A (ja) | 1990-08-08 | 1992-03-27 | Asahi Chem Ind Co Ltd | アルドースリダクターゼ阻害剤 |
| US5728704A (en) | 1992-09-28 | 1998-03-17 | Pfizer Inc. | Substituted pyridmidines for control of diabetic complications |
| US5464961A (en) | 1993-09-10 | 1995-11-07 | Olin Corporation | Arcjet anode |
| US5624949A (en) | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
| IL113112A (en) | 1994-03-28 | 2000-06-01 | Nissan Chemical Ind Ltd | Pyridine substituted thiazolidinediones and pharmaceutical compositions comprising them |
| EP0847379A1 (en) | 1995-08-28 | 1998-06-17 | American Home Products Corporation | Phenoxy acetic acids as aldose reductase inhibitors and antihyperglycemic agents |
| PL179170B1 (pl) | 1995-09-15 | 2000-07-31 | Inst Lekow | Nowe zwiazki,pochodne genisteiny PL PL PL PL |
| YU49315B (sh) | 1995-11-20 | 2005-06-10 | Elli Lilly And Company | Inhibitor protein kinaze c, njegove farmaceutske formulacije i postupak za dobijanje |
| US6696407B1 (en) | 1997-03-21 | 2004-02-24 | The Regents Of The University Of California | Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF |
| WO1999015529A1 (en) | 1997-09-23 | 1999-04-01 | Novo Nordisk A/S | MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| CA2383983C (en) | 1998-03-31 | 2009-09-29 | The Institutes For Pharmaceutical Discovery, Llc | Substituted indolealkanoic acids |
| EP0982306A3 (en) | 1998-08-21 | 2000-07-05 | Pfizer Products Inc. | Polymorph of zopolrestat monohydrate |
| AP2005003199A0 (en) | 1999-04-01 | 2005-03-31 | Pfizer Prod Inc | Aminopyrimidines as sorbitol dehydrogenase inhibitors |
| JP4511655B2 (ja) | 1999-08-25 | 2010-07-28 | ユニチカ株式会社 | ソルビトール脱水素酵素、それを産生する微生物およびその製造方法 |
| US6916824B1 (en) | 1999-11-12 | 2005-07-12 | Kansas State University Research Foundation | Methods of treating cataracts and diabetic retinopathy with tricyclic pyrones |
| EP1106210A3 (en) * | 1999-12-07 | 2003-12-03 | Pfizer Products Inc. | Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications |
| US6570013B2 (en) | 2000-02-16 | 2003-05-27 | Pfizer Inc | Salts of zopolrestat |
| CA2442476A1 (en) | 2001-03-30 | 2002-10-10 | Pfizer Products Inc. | Pyridazinone aldose reductase inhibitors |
| WO2003061660A1 (en) | 2002-01-23 | 2003-07-31 | Eli Lilly And Company | Melanocortin receptor agonists |
| WO2003105864A1 (en) | 2002-06-13 | 2003-12-24 | Board Of Regents, The University Of Texas System | Methods and compositions involving aldose reductase inhibitors |
| CA2489470A1 (en) | 2002-06-14 | 2003-12-24 | Takeda Pharmaceutical Company Limited | Prodrug and process for producing the same |
| PT2441467E (pt) | 2003-01-31 | 2015-10-12 | Sinai School Medicine | Terapia combinada para o tratamento de transtornos associados a uma deficiência proteica |
| US7572910B2 (en) | 2003-02-20 | 2009-08-11 | Pfizer, Inc. | Pyridazinone aldose reductase inhibitors |
| JP5044122B2 (ja) * | 2003-10-24 | 2012-10-10 | 株式会社明治 | 後期糖化最終生成物形成の新規阻害剤及びアルドース還元酵素阻害剤 |
| US20070021366A1 (en) | 2004-11-19 | 2007-01-25 | Srivastava Satish K | Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use |
| US20110092566A1 (en) | 2004-11-19 | 2011-04-21 | Srivastava Satish K | Treatment of cancer with aldose reductase inhibitors |
| SI2137217T1 (sl) | 2007-04-05 | 2014-07-31 | Morphotek, Inc. | Postopki za inhibiranje vezave endosialina na ligande |
| CN101143868A (zh) | 2007-09-04 | 2008-03-19 | 北京理工大学 | 醛糖还原酶抑制剂结构及用途 |
| EP2065038A1 (en) | 2007-11-30 | 2009-06-03 | Pharnext | New therapeutic approaches for treating Charcot-Marie-Tooth disease |
| US20100215726A1 (en) | 2009-02-25 | 2010-08-26 | Peter Thomas Roth | Compositions for Diminishing the Appearance of Wrinkles |
| WO2011037985A1 (en) | 2009-09-23 | 2011-03-31 | The Trustees Of The University Of Pennsylvania | Aminothienopyridazine inhibitors of tau assembly |
| EP2502079B1 (en) | 2009-11-20 | 2015-01-28 | Pharnext | New diagnostic tools for charcot-marie-tooth disease |
| US8916563B2 (en) | 2010-07-16 | 2014-12-23 | The Trustees Of Columbia University In The City Of New York | Aldose reductase inhibitors and uses thereof |
| EP3192796B1 (en) | 2010-07-16 | 2019-09-04 | The Trustees of Columbia University in the City of New York | Aldose reductase inhibitors and uses thereof |
| WO2012138384A1 (en) | 2010-11-15 | 2012-10-11 | U.S. Army Medical Research And Materiel Command | Field sampling kit and methods for collecting and detecting alkyl methylphosphonic acids |
| CN102512407B (zh) | 2011-11-23 | 2014-05-21 | 中山大学 | 一种β-苯丙氨酸类化合物作为醛糖还原酶抑制剂的应用 |
| WO2013123403A1 (en) | 2012-02-15 | 2013-08-22 | Sanford-Burnham Medical Research Institute | Theranostics platform and methods of use |
| GB201205739D0 (en) | 2012-03-30 | 2012-05-16 | Ucl Business Plc | Treatment of acute inflammation in the respiratory tract |
| EP2877214B1 (en) | 2012-07-26 | 2019-04-24 | Joslin Diabetes Center, Inc. | Predicting diabetic complications |
| US20170362237A1 (en) | 2016-06-17 | 2017-12-21 | Banavara L. Mylari | Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications |
| EP2967339B1 (en) | 2013-03-15 | 2019-11-20 | Biogen MA Inc. | Assessment of labeled probes in a subject |
| JP6187364B2 (ja) | 2014-03-31 | 2017-08-30 | ブラザー工業株式会社 | 印刷装置 |
| JP6500992B2 (ja) | 2015-09-01 | 2019-04-17 | 株式会社村田製作所 | コイル内蔵部品 |
| EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
| DK3352754T3 (da) | 2016-06-21 | 2020-12-07 | Univ Columbia | Aldosereduktaseinhibitorer og fremgangsmåder til anvendelse deraf |
| JP2019535265A (ja) | 2016-11-14 | 2019-12-12 | メモリアル スローン ケタリング キャンサー センター | 幹細胞由来シュワン細胞 |
| CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| WO2018200258A1 (en) | 2017-04-27 | 2018-11-01 | Applied Therapeutics Inc. | Aldose reductase inhibitors and uses thereof |
| IL272246B2 (en) | 2017-07-28 | 2026-01-01 | Applied Therapeutics Inc | History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications |
| US11329472B2 (en) | 2018-07-20 | 2022-05-10 | Texas Instruments Incorporated | Methods and apparatus to prevent undesired triggering of short circuit or over current protection |
| CA3110162A1 (en) | 2018-08-20 | 2020-02-27 | Maggie's Pearl, Llc | Methods for treating congenital disorders of glycosylation |
| US20220071880A1 (en) | 2019-02-12 | 2022-03-10 | Applied Therapeutics, Inc. | Methods for treating cutaneous aging |
| CN113840825A (zh) | 2019-04-01 | 2021-12-24 | 应用治疗公司 | 醛糖还原酶抑制剂 |
| WO2020227430A1 (en) | 2019-05-07 | 2020-11-12 | University Of Miami | Treatment and detection of inherited neuropathies and associated disorders |
| CA3153108A1 (en) | 2019-10-08 | 2021-04-15 | Riccardo Perfetti | Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency |
| EP4125909A1 (en) | 2020-03-31 | 2023-02-08 | Applied Therapeutics Inc. | Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy |
| IL297779A (en) | 2020-05-01 | 2022-12-01 | Applied Therapeutics Inc | Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency |
-
2018
- 2018-07-26 IL IL272246A patent/IL272246B2/en unknown
- 2018-07-27 EP EP24167651.9A patent/EP4417260A3/en active Pending
- 2018-07-27 PL PL18838277.4T patent/PL3658142T3/pl unknown
- 2018-07-27 EP EP18838277.4A patent/EP3658142B1/en active Active
- 2018-07-27 WO PCT/US2018/044199 patent/WO2019023648A1/en not_active Ceased
- 2018-07-27 PT PT188382774T patent/PT3658142T/pt unknown
- 2018-07-27 LT LTEPPCT/US2018/044199T patent/LT3658142T/lt unknown
- 2018-07-27 US US16/634,509 patent/US11590131B2/en active Active
- 2018-07-27 SG SG11202000730QA patent/SG11202000730QA/en unknown
- 2018-07-27 SI SI201831127T patent/SI3658142T1/sl unknown
- 2018-07-27 CN CN202411416540.8A patent/CN119633117A/zh active Pending
- 2018-07-27 CA CA3071114A patent/CA3071114A1/en active Pending
- 2018-07-27 IL IL322622A patent/IL322622A/en unknown
- 2018-07-27 ES ES18838277T patent/ES2983586T3/es active Active
- 2018-07-27 HU HUE18838277A patent/HUE067079T2/hu unknown
- 2018-07-27 MX MX2020001057A patent/MX2020001057A/es unknown
- 2018-07-27 JP JP2020527861A patent/JP7307059B2/ja active Active
- 2018-07-27 AU AU2018307964A patent/AU2018307964B2/en active Active
- 2018-07-27 CN CN202411417180.3A patent/CN119971038A/zh active Pending
- 2018-07-27 CN CN201880059100.8A patent/CN111065392B/zh active Active
- 2018-07-27 DK DK18838277.4T patent/DK3658142T3/da active
- 2018-07-27 FI FIEP18838277.4T patent/FI3658142T3/fi active
- 2018-07-27 HR HRP20240840TT patent/HRP20240840T1/hr unknown
-
2020
- 2020-01-27 MX MX2022015186A patent/MX2022015186A/es unknown
-
2022
- 2022-10-24 JP JP2022169791A patent/JP7541064B2/ja active Active
-
2023
- 2023-01-23 US US18/158,089 patent/US20230346782A1/en active Pending
-
2024
- 2024-01-30 AU AU2024200537A patent/AU2024200537A1/en not_active Abandoned
- 2024-08-15 JP JP2024135647A patent/JP2024159794A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020528938A5 (https=) | ||
| JP6835472B2 (ja) | 癌の処置のための組成物 | |
| TWI752335B (zh) | Bcl-2抑制劑與MDM2抑制劑的組合產品及其在預防及/或治療疾病中的用途 | |
| JP6883049B2 (ja) | アミノチアゾール化合物及びその使用 | |
| JP2016513661A5 (https=) | ||
| RU2016134751A (ru) | Соединения | |
| TW202007396A (zh) | Bcl-2抑制劑或Bcl-2/Bcl-xL抑制劑與BTK抑制劑的組合產品及其在預防和/或治療疾病中的用途 | |
| IL286427B2 (en) | Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease | |
| RU2015143542A (ru) | Ингибиторы jak2 и alk2 и способы их использования | |
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2017507122A5 (https=) | ||
| JP2021501208A5 (https=) | ||
| JP2015536986A (ja) | 併用療法 | |
| CA2834414A1 (en) | Multiple myeloma treatment | |
| ECSP066948A (es) | Benzoxazinas para el tratamiento de enfermedades de las vías respiratorias | |
| CN110267954A (zh) | 苯胺取代的1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途 | |
| JP2016508969A5 (https=) | ||
| JPWO2022268152A5 (https=) | ||
| JP6863742B2 (ja) | 新規アントラニルアミドとその使用 | |
| US10703745B2 (en) | Acyl phosphonamidates and acyl benzylamines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer | |
| US20140066465A1 (en) | CANCER TREATMENT USING TYROSINE KINASE AND NF-kB INHIBITORS | |
| JP2020519659A5 (https=) | ||
| RU2004139041A (ru) | Применение гетероаренкарбоксамидов в качестве дофамин-d3 лигандов для лечения заболеваний центральной нервной системы | |
| CA2608163A1 (en) | Hydralazine compositions and methods | |
| WO2022011325A1 (en) | Methods for the prevention and treatment of hearing loss |